从长凳到床边
医学
细胞周期蛋白依赖激酶4
生物信息学
癌症治疗
计算机科学
肿瘤科
计算生物学
癌症研究
癌症
内科学
生物
医学物理学
细胞周期蛋白依赖激酶2
细胞周期
作者
Ali Hassanzadeh,Navid Shomali,Amin Kamrani,Mohammad Sadegh Soltani‐Zangbar,Hadi Nasiri,Morteza Akbari
出处
期刊:PubMed
日期:2024-01-01
卷期号:23: 862-882
标识
DOI:10.17179/excli2024-7076
摘要
A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI